Kemoterapi Adjuvan pada Kanker Kolorektal
DOI:
https://doi.org/10.25077/jka.v8i1S.925Abstract
Kanker kolorektal (colorectal cancer/CRC) memiliki insiden, morbiditas dan mortalitas yang tinggi. Pembedahan sebagai terapi kuratif terbaik dalam penanganan CRC belum memberikan hasil klinis yang memuaskan karena tingginya kejadian rekurensi pasca pembedahan akibat adanya residu mikroskopis sel kanker. Kemoterapi adjuvan dikembangkan untuk menangani hal tersebut namun pemberiannya dihadapkan pada masalah efek samping dan resiko toksisitas. Penentuan stadium, kondisi pasien, indikasi kemoterapi dan pemilihan regimen yang tepat perlu dilakukan.Downloads
Published
How to Cite
Issue
Section
License
Authors retain copyright and grant the Jurnal Kesehatan Andalas right of first publication with the work simultaneously licensed under a Creative Commons Attribution-ShareAlike (CC BY-SA 4.0) license that allows others to share (copy and redistribute the material in any medium or format) and adapt (remix, transform, and build upon the material) the work for any purpose, even commercially with an acknowledgement of the work's authorship and initial publication in Jurnal Kesehatan Andalas.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in Jurnal Kesehatan Andalas.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).










